LPTX Stock Price, Leap Therapeutics Inc Quote, Chart

Market Summary

USD2.65-0.09

Delayed

-3.28%

LPTX Stock Price

View Fullscreen

LPTX RSI Chart

LPTX Valuation

Market Cap

101.4M

Price/Earnings (Trailing)

-1.9

Price/Sales (Trailing)

92.1

EV/EBITDA

-0.57

Price/Free Cashflow

-2.18

LPTX Price/Sales (Trailing)

LPTX Profitability

EBT Margin

-7394.55%

Return on Equity

-112.66%

Return on Assets

-92.08%

Free Cashflow Yield

-45.93%

LPTX Fundamentals

LPTX Revenue

Revenue (TTM)

1.1M

Rev. Growth (Yr)

-9.56%

Rev. Growth (Qtr)

-38.5%

LPTX Earnings

Earnings (TTM)

-53.4M

Earnings Growth (Yr)

66.99%

Earnings Growth (Qtr)

-10.87%

Breaking Down LPTX Revenue

Last 7 days

-4.7%

Last 30 days

-11.7%

Last 90 days

-15.3%

Trailing 12 Months

314.1%

How does LPTX drawdown profile look like?

LPTX Financial Health

Current Ratio

5.38

LPTX Investor Care

Shares Dilution (1Y)

220.44%

Diluted EPS (TTM)

-1.71

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	2.3M	2.0M	1.9M	1.1M
2022	1.4M	1.6M	1.8M	2.1M
2021	1.8M	1.8M	2.9M	1.2M
2020	2.2M	2.5M	2.8M	1.8M
2019	1.0M	1.3M	1.6M	1.9M
2018	1.5M	1.2M	995.8K	756.0K
2017	2.8M	2.4M	2.1M	1.7M
2016	0	0	0	3.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Leap Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 26, 2024	mirabelli christopher	acquired	-	-	5,000	chairman of the board
Jan 26, 2024	lawlor augustine	acquired	-	-	5,000	chief operating officer
Jan 26, 2024	onsi douglas e	acquired	-	-	7,500	ceo,cfo,pres.,gc,treas.,&sec.
Jan 26, 2024	sirard cynthia	acquired	-	-	5,000	chief medical officer
Jan 26, 2024	o'mahony john mark	acquired	-	-	5,000	chief manufacturing officer
Mar 17, 2023	onsi douglas e	acquired	-	-	660,606	ceo,cfo,pres.,gc,treas.,&sec.
Sep 24, 2021	beigene, ltd.	bought	7,249,830	2.85	2,543,800	-
Dec 28, 2020	healthcare ventures viii, l.p.	sold	-	-	-2,618,410	-
Jun 22, 2020	perceptive advisors llc	bought	3,500,000	2.00	1,750,000	-
Feb 05, 2019	mirabelli christopher	bought	999,999	1.75	571,428	ceo, president, chairman

Which funds bought or sold LPTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	40,320	40,320	-%
May 15, 2024	BAKER BROS. ADVISORS LP	unchanged	-	-1,740,680	3,117,990	0.04%
May 15, 2024	PERCEPTIVE ADVISORS LLC	sold off	-100	-186,404	-	-%
May 15, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	reduced	-49.09	-2,631,600	1,276,800	-%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	reduced	-25.19	-309,460	285,716	0.02%
May 15, 2024	Royal Bank of Canada	sold off	-100	-2,000	-	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	48,627	48,627	-%
May 15, 2024	CITADEL ADVISORS LLC	added	4.18	-937,886	1,892,110	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-93,871	168,147	-%
May 15, 2024	MORGAN STANLEY	reduced	-12.98	-2,298	2,908	-%

Are Funds Buying or Selling LPTX?

Are funds buying LPTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LPTX

No. of Funds

Unveiling Leap Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	samsara biocapital, l.p.	6.4%	2,442,352	SC 13G
Apr 19, 2024	gilead sciences, inc.	13.9%	5,319,148	SC 13G
Feb 14, 2024	perceptive advisors llc	4.0%	1,068,497	SC 13G/A
Feb 14, 2023	perceptive advisors llc	6.8%	6,726,496	SC 13G/A
Feb 15, 2022	perceptive advisors llc	9.6%	8,476,496	SC 13G/A
Feb 14, 2022	hhlr advisors, ltd.	0%	0	SC 13G/A
Feb 11, 2022	artal international s.c.a.	4.5%	4e+06	SC 13G/A
Feb 10, 2022	eli lilly & co	3.5%	3,151,605	SC 13G/A
Sep 29, 2021	beigene, ltd.	13.2%	12,153,074	SC 13D/A
Feb 16, 2021	hillhouse capital advisors, ltd.	6.2%	3,716,240	SC 13G

Recent SEC filings of Leap Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	DEFA14A	DEFA14A
May 13, 2024	8-K	Current Report
May 13, 2024	10-Q	Quarterly Report
May 10, 2024	S-3	S-3
May 09, 2024	EFFECT	EFFECT
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	ARS	ARS
Apr 25, 2024	SC 13G	Major Ownership Report
Apr 19, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Leap Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Leap Therapeutics Inc News

Latest updates

Leap Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-38.5%	246,000	400,000	554,000	298,000	272,000	775,000	652,000	587,000	814,333	1,041,667	1,269,000	375,000	375,000	839,500	228,000	375,000	375,000	1,794,000	927,500	61,000	75,000
Operating Expenses	0.0%	14,825,000	14,820,000	14,833,000	14,662,000	42,726,000	13,943,000	15,288,000	16,900,000	10,632,000	10,863,000	12,515,000	10,001,000	9,547,000	7,529,000	7,883,000	7,871,000	6,756,000	8,272,000	7,923,000	8,461,000	8,795,000
S&GA Expenses	-100.0%	-	3,135,000	3,330,000	3,558,000	3,784,000	2,909,000	3,186,000	2,855,000	2,848,000	2,793,000	2,438,000	2,795,000	2,740,000	2,428,000	2,514,000	2,521,000	2,153,000	2,604,000	2,151,000	2,325,000	2,005,000
R&D Expenses	-3.3%	11,299,000	11,685,000	11,503,000	11,104,000	38,942,000	11,034,000	12,102,000	14,045,000	7,784,000	8,070,000	10,077,000	7,206,000	6,807,000	5,101,000	5,369,000	5,350,000	4,603,000	5,668,000	5,772,000	6,136,000	6,790,000
EBITDA Margin	0%	-73.88	-73.88	-28.64	-27.23	-23.79	-26.51	-21.98	-24.74	-28.30	-33.07	-12.75	-17.80	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	5,000	11,000	17,000	21,000	2,000	9,000	16,000	14,000	-3,000	17,000	13,000	12,000	2,000	5,000	9,000	7,000
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-10,812,000	-11,139,000	-9,526,000	-9,134,000	-6,712,000	-7,057,000	-6,516,000	-7,231,000	-7,999,000	-7,935,000	-8,366,000	-8,603,000
EBT Margin	0%	-73.95	-73.95	-28.67	-27.27	-23.82	-26.55	-22.01	-24.79	-28.35	-33.12	-12.77	-17.84	-	-	-	-	-	-	-	-	-
Net Income	-10.9%	-13,820,000	-12,465,000	-13,696,000	-13,390,000	-41,863,000	-12,102,000	-15,094,000	-17,024,000	-10,376,000	-10,788,000	-11,139,000	-9,526,000	-9,134,000	-6,710,000	-7,057,000	-6,516,000	-7,231,000	-7,996,000	-7,935,000	-8,366,000	-8,603,000
Net Income Margin	34.4%	-48.48	-73.95	-42.68	-41.29	-37.66	-26.62	-28.88	-30.10	-29.21	-33.11	-12.77	-17.84	-	-	-	-	-	-	-	-	-
Free Cashflow	-49.5%	-15,516,000	-10,380,000	-10,488,000	-10,185,000	-12,700,000	-13,014,000	-12,253,000	-12,259,000	-11,518,000	-10,716,000	-8,102,000	-7,752,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-20.4%	58.00	73.00	83.00	96.00	107	70.00	82.00	94.00	106	118	128	38.00	46.00	54.00	61.00	68.00	29.00	7.00	14.00	20.00	26.00
Current Assets	-21.5%	56.00	72.00	82.00	94.00	105	68.00	80.00	92.00	105	117	125	36.00	44.00	52.00	58.00	65.00	26.00	4.00	11.00	17.00	23.00
Cash Equivalents	-22.3%	55.00	71.00	81.00	91.00	102	66.00	78.00	91.00	103	115	125	36.00	43.00	52.00	52.00	65.00	25.00	4.00	10.00	16.00	22.00
Net PPE	-100.0%	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-16.5%	11.00	13.00	11.00	12.00	11.00	11.00	12.00	11.00	7.00	10.00	11.00	8.00	7.00	8.00	7.00	8.00	11.00	9.00	9.00	9.00	9.00
Current Liabilities	-17.7%	10.00	13.00	11.00	12.00	10.00	11.00	12.00	10.00	7.00	10.00	11.00	8.00	7.00	7.00	7.00	7.00	9.00	8.00	8.00	8.00	8.00
Shareholder's Equity	-21.2%	47.00	60.00	72.00	84.00	28.00	59.00	70.00	83.00	99.00	108	117	30.00	38.00	47.00	53.00	60.00	18.00	-	6.00	11.00	17.00
Retained Earnings	-3.5%	-413	-399	-387	-373	-360	-318	-306	-290	-273	-263	-252	-241	-232	-222	-216	-209	-202	-195	-187	-179	-170
Additional Paid-In Capital	0.3%	461	460	458	457	388	377	375	374	373	372	370	272	271	270	269	269	220	193	192	190	188
Shares Outstanding	0.1%	26.00	26.00	26.00	26.00	12.00	10.00	11.00	11.00	11.00	6.00	8.00	8.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	78.00	-	-	-	94.00	-	-	-	86,766,207	-	-	-	109	-	-	-	28.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-49.5%	-15,516	-10,380	-10,488	-10,185	-12,700	-13,014	-12,253	-12,259	-11,518	-10,716	-8,102	-7,752	-8,587	-5,988	-6,592	-9,451	-3,926	-5,894	-6,957	-7,183	-6,868
Share Based Compensation	-0.4%	1,248	1,253	1,300	1,265	1,310	1,457	1,253	1,266	1,204	938	1,003	912	833	715	670	617	570	936	950	899	947
Cashflow From Investing	-	-	-	-	-348	49,317	-	-	-	-	-	-	-	-	-	-	-	-	15.00	-	-	-
Cashflow From Financing	-	29.00	-	-1.00	-	-29.00	-	-	-	-210	755	97,262	4.00	14.00	-	-385	48,777	25,605	-19.00	1,254	1,260	12,322

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LPTX Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 11,299	$ 38,942
General and administrative	3,526	3,784
Total operating expenses	14,825	42,726
Loss from operations	(14,825)	(42,726)
Interest income	775	848
Australian research and development incentives	246	272
Foreign currency loss	(16)	(307)
Change in fair value of Series X preferred stock warrant liability		50
Net loss	$ (13,820)	$ (41,863)
Net loss per share
Basic (in dollars per share)	$ (0.51)	$ (3.24)
Diluted (in dollars per share)	$ (0.51)	$ (3.24)
Weighted average common shares outstanding
Basic (in shares)	27,014,100	12,934,427
Diluted (in shares)	27,014,100	12,934,427

LPTX Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 54,921	$ 70,643
Research and development incentive receivable	738	771
Prepaid expenses and other current assets	526	183
Total current assets	56,185	71,597
Property and equipment, net		5
Right of use assets, net	577	257
Research and development incentive receivable, net of current portion	245
Deferred costs	39
Deposits	917	966
Total assets	57,963	72,825
Current liabilities:
Accounts payable	5,951	6,465
Accrued expenses	4,056	5,957
Lease liability - current portion	430	262
Total current liabilities	10,437	12,684
Non current liabilities:
Lease liability, net of current portion	154
Total liabilities	10,591	12,684
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.001 par value; 240,000,000 shares authorized; 25,603,471 and 25,565,414 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	26	26
Additional paid-in capital	460,868	459,591
Accumulated other comprehensive income (loss)	(120)	106
Accumulated deficit	(413,402)	(399,582)
Total stockholders' equity	47,372	60,141
Total liabilities and stockholders' equity	$ 57,963	$ 72,825

About Leap Therapeutics Inc

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

CEO	Mr. Douglas E. Onsi J.D.
WEBSITE	leaptx.com
INDUSTRY	Biotechnology
EMPLOYEES	44

Leap Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Leap Therapeutics Inc? What does LPTX stand for in stocks?

LPTX is the stock ticker symbol of Leap Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Leap Therapeutics Inc (LPTX)?

As of Fri May 17 2024, market cap of Leap Therapeutics Inc is 101.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LPTX stock?

You can check LPTX's fair value in chart for subscribers.

What is the fair value of LPTX stock?

You can check LPTX's fair value in chart for subscribers. The fair value of Leap Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Leap Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LPTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Leap Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether LPTX is over valued or under valued. Whether Leap Therapeutics Inc is cheap or expensive depends on the assumptions which impact Leap Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LPTX.

What is Leap Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, LPTX's PE ratio (Price to Earnings) is -1.9 and Price to Sales (PS) ratio is 92.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LPTX PE ratio will change depending on the future growth rate expectations of investors.